Navigation Links
Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
Date:3/18/2013

ing OMS103HP to vehicle control in 344 patients undergoing arthroscopic partial meniscectomy surgery.  The pre-specified primary endpoint was the Symptoms Subscale of the KOOS – a patient-reported measure that is comprised of questions about knee swelling, clicking, catching and stiffness. In addition, pain measured in the early postoperative period was a pre-specified secondary endpoint. Although the Symptoms Subscale of the KOOS did not reach statistical significance, OMS103HP achieved statistically significant (p=0.0003) reduction of postoperative pain. The pain reduction data were similar in magnitude to those in the Phase 2 clinical trial. Omeros expects to conduct two concurrent Phase 3 clinical trials with reduction of early postoperative pain as the pre-specified primary endpoint and to begin enrolling patients in the first of these two planned trials in the first half of 2013. Each of these two additional Phase 3 clinical trials will enroll substantially fewer subjects than were required for the first Phase 3 trial assessing KOOS as the primary endpoint given the increased statistical power associated with reduction in early postoperative pain shown in the Phase 2 and first Phase 3 meniscectomy clinical trials.

About Omeros CorporationOmeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Be
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
2. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
3. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
4. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
5. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
6. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
7. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
8. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
9. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
10. FibeRio® Technology Corporation Announces Strategic Investment Financing Led by SABIC and Aster Capital
11. Celsion Corporation Announces $15 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Oct. 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... that management will present a company overview at the Nomura ... ET in Boston, MA. ... the "Investors & Media" section of the Company,s website, ... website within 48 hours and will be archived for a ...
(Date:10/30/2014)... flooding that devastated a wide swath of Colorado last ... roads and other infrastructure had been upgraded or modernized, ... Colorado Denver. , "People need to understand the importance ... professor of structural engineering at the CU Denver College ... study. "There is an assumption that a bridge will ...
(Date:10/27/2014)... and TORONTO , Oct. ... www.generex.com ) (OTCQB: GNBT) today announced two presentations ... triggered by its novel proprietary cancer immunotherapeutic AE37 ... breast cancer patients. The AE37 cancer vaccine is ... Express, Inc. ( www.antigenexpress.com ). The presentations are ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 Called ... reducing and eliminating several types of pediatric brain ... been achieved in over 30 years of research ... Light Foundation, proves that one mom's determination can ... just before Halloween trick-or-treating, and it’s only fitting ...
Breaking Biology Technology:Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3
... BioMarin,Pharmaceutical Inc. (Nasdaq: BMRN ) today announced ... a company,update at the Credit Suisse 2008 Annual Healthcare ... 10:30 a.m. MST., Interested parties may access a ... section of the BioMarin website, http://www.BMRN.com .,A replay ...
... Stock Exchange Symbol: MS, EDMONTON, Nov. 5 /PRNewswire-FirstCall/ - ... of multiple sclerosis (MS), today,announced that Mr. Kevin Giese, President ... Healthcare Conference in New York., WHEN: ... WHERE: New York Palace Hotel, New York., ...
... that management will present at the following,investor conferences in November., ... New York Palace Hotel Wednesday, November 12, 2008 ... Conference The St. Regis Hotel, New York Tuesday, ... will be audio webcast live and available for replay,from Dendreon,s ...
Cached Biology Technology:BioMarin to Present at the Credit Suisse Healthcare Conference 2BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference 2
(Date:10/29/2014)... of kidney cancer patients in Europe sheds light on ... an apparent link between exposure to aristolochic acid and ... research, by an international team led by scientists from ... Montreal, underscores the importance of investigating possible sources of ... of the Aristolochia genus, also has been suspected of ...
(Date:10/28/2014)... North America, Europe and China have published a paper ... Sciences that reveals important details about key transitions ... From strange and exotic algae, mosses, ferns, trees and ... and vegetables we eat and the ornamental plants adorning ... a billion years of history., "Our study generated DNA ...
(Date:10/28/2014)... a novel environment are linked to individual differences ... study completed at the University of Eastern Finland ... The study used novel, long-term observations of individual ... analyse if behaviours predict the vulnerability to fishing ... hatchery rearing environments. Based on the results, ...
Breaking Biology News(10 mins):Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3New study uses DNA sequences to look back in time at key events in plant evolution 2New study uses DNA sequences to look back in time at key events in plant evolution 3Fish 'personality' linked to vulnerability to angling 2
... have elucidated a key mechanism by which cancer cells ... and raw materials required to sustain runaway growth. ... Ludwig Cancer Research study also reveals how the aggressive ... therapies that should disrupt this capabilityknown as the Warburg ...
... animals will choose to steer clear of dirt but their ... risk of disease as a result. A study of ... near to used nesting material and droppings left by other mice. ... opportunity to eat outweighs an increased risk of disease from other ...
... to learn that individual "molecular muscles" within cells respond to ... cells "feel" the environment and appropriately adapt their shapes and ... 20 in the journal Nature Materials , specifically sheds ... internal signals. A computer model the researchers developed, ...
Cached Biology News:Targeting cancer's sweet tooth 2Targeting cancer's sweet tooth 3Clean living is a luxury wild animals can't afford, study suggests 2Cells' 'molecular muscles' help them sense and respond to their environments 2Cells' 'molecular muscles' help them sense and respond to their environments 3